MAM
ALXN

Madison Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Madison Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,965
Closed -$545K – 332
2021
Q2 		$545K Hold
2,965
– – 0.01% 289
2021
Q1 		$453K Hold
2,965
– – 0.01% 288
2020
Q4 		$463K Hold
2,965
– – 0.01% 276
2020
Q3 		$339K Hold
2,965
– – 0.01% 254
2020
Q2 		$333K Hold
2,965
– – 0.01% 255
2020
Q1 		$266K Hold
2,965
– – 0.01% 257
2019
Q4 		$321K Buy
+2,965
New +$317K ﹤0.01% 277

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Madison Asset Management's ALXN Position: Q3 2021 in Review

Madison Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 2,965 shares — an estimated $545K sold.

Madison Asset Management first reported a position in ALXN in Q4 2019 and held it in 7 quarters. The position peaked at $545K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Madison Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Madison Asset Management sold 2,965 Alexion Pharmaceuticals shares in Q3 2021, an estimated $545K.
  • Madison Asset Management first reported a position in Alexion Pharmaceuticals in Q4 2019 and held it in 7 quarters.
  • Madison Asset Management's Alexion Pharmaceuticals position peaked at $545K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Madison Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.